Robichaux et al. studied a large database of EGFR mutant NSCLC, developing a new preclinical model of 76 different EGFR mutations treated with 18 different EGFR inhibitors (first-, second- and third-generation, as well as ex20ins TKIs) [24,37]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.